The legacy of proton therapy at MGH
Proton therapy has been part of MGH's cancer treatment arsenal since the 1960s. Initially, treatments were conducted using an experimental cyclotron on Harvard University's campus, which posed significant limitations. The system had only one fixed beam and poor imaging capabilities. 1 As Dr. Zietman explains, “we may have had great treatment, but we couldn’t see our target, we were very limited”.
Approximately 20 years ago, the MGH put together its own patient-dedicated facility, together with IBA. The introduction of a dedicated patient facility marked a turning point, allowing for patient-centered care.
Proton therapy advancements over two decades
Proton therapy has evolved dramatically over the last two decades, enabling the delivery of more patient-friendly cancer treatments. The new proton therapy facility features rotating gantry, moving away from the fixed beam approach and allowing for more versatile treatment options. Previously, patients had to be rotated within the beam, facing technical limitations or difficulties for the patients to move accurately. Rotating gantry in proton therapy enables clinicians to aim the beam at the target tumors within the patient, and the patient couch can also be rotated to achieve optimum beam directions and avoid as much normal tissue as possible.2 Enhanced imaging capabilities further support this precision, allowing for better visualization of the tumor and surrounding tissues visualization. As Dr. Zietman explains, “outcomes are better, both in terms of cancer control and side effects of treatment and quality of life is greatly improved, in long-term survivors”.
Discover how to maximize cancer patient care thanks to IBA’s expertise and our Proteus systems versatility here.
The importance of long-term partnerships
Dr. Zietman emphasizes the unique nature of the relationship between healthcare providers and proton therapy equipment vendors. This partnership is crucial as it involves a significant capital investment and a commitment that spans decades. Choosing a stable and innovative partner is essential for ensuring that the technology remains cutting-edge and continues to meet the evolving needs of cancer treatment through the entire length of the machine’s lifespan and the restoration that may follow.
Discover IBA’s engagement in providing proton therapy solutions with unmatched long-term value here.
Excitement for the ProteusPLUS system restoration
The upcoming restoration of IBA’s ProteusPLUS system is generating excitement at MGH. This upgrade is expected to enhance the hospital's ability to conduct clinical trials, allowing for further research into the effectiveness of proton therapy in treating various types of cancer. Dr. Shin highlights that the ProteusPLUS system restoration will enable “studies that look to assess whether protons can either cure or control more disease because we have better imaging system and conformal treatment and also to reduce side effects by reducing radiation to unaffected normal tissues”.
Conclusion
The restoration of the first proton therapy system at MGH signifies a pivotal moment in cancer treatment. With technological advancements and a commitment to patient-centered care, the future of proton therapy looks brighter than ever. As Dr. Shih and Dr. Zietman highlight, IBA partners with Proton Therapy facilities to continue pushing the boundaries of what's possible in cancer treatment and to help patients look forward to more effective and less harmful options in their fight against cancer.
References
- Hallemeier, C.L. et al. A brief overview of the use of proton beam radiotherapy for gastrointestinal cancers. J Gastrointest Oncol. 2020;11(1):139–143. DOI: 10.21037/jgo.2019.07.06
- Mohan, R. et al. Proton therapy – Present and future. Adv Drug Deliv Rev. 2017;10926–44. DOI: 10.1016/j.addr.2016.11.006
Notes
Disclaimer: The statements of the healthcare professional included in this testimonial reflect only his opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom he is affiliated or IBA.
